The potential role of thiazolidinediones in atrial fibrillation

dc.contributor.authorLiu, T.en
dc.contributor.authorKorantzopoulos, P.en
dc.contributor.authorLi, G.en
dc.contributor.authorLi, J.en
dc.date.accessioned2015-11-24T19:35:28Z
dc.date.available2015-11-24T19:35:28Z
dc.identifier.issn1874-1754-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23709
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subjectAtrial Fibrillation/*drug therapy/metabolism/physiopathologyen
dc.subjectDiabetes Mellitus, Type 2/drug therapyen
dc.subjectHumansen
dc.subjectHypoglycemic Agents/therapeutic useen
dc.subjectInflammation/physiopathologyen
dc.subjectOxidative Stress/physiologyen
dc.subjectPeroxisome Proliferator-Activated Receptors/metabolismen
dc.subjectThiazolidinediones/*therapeutic useen
dc.titleThe potential role of thiazolidinediones in atrial fibrillationen
heal.abstractThiazolidinediones (TZDs) represent insulin sensitizing drugs that are being increasingly used for the treatment of type 2 diabetes. These agents have also pleiotropic properties that possibly contribute to their favorable cardiovascular effects. In particular, TZDs have anti-inflammatory and anti-oxidant potential while they modulate cardiovascular remodeling. On the other hand, atrial electrical and structural remodeling constitutes the substrate for atrial fibrillation (AF) development and perpetuation. Of note, inflammation and oxidative stress have been recently implicated in the pathogenesis of AF while non-channel blocking drugs with pleiotropic properties, including anti-inflammatory and anti-oxidant, seem to favorably affect atrial remodeling. It is therefore reasonable to assume that TZDs may have a role in the management of AF. Despite some limited observations, no study to date has examined the effect of TZDs therapy on AF development. In addition, the role of these agents in atrial remodeling has not been clarified yet.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1016/j.ijcard.2007.05.051-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17655946-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0167527307011783/1-s2.0-S0167527307011783-main.pdf?_tid=d34f2fe3c78d13ef25e129333e34ae66&acdnat=1333964361_e83cce29bb2bce26e8667b4e618bd845-
heal.journalNameInt J Cardiolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2008-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: